Biogen (NASDAQ:BIIB) Stock Acquired Rep. Robert Bresnahan, Jr.

Representative Robert Bresnahan, Jr. (R-Pennsylvania) recently bought shares of Biogen Inc. NASDAQ: BIIB. In a filing disclosed on June 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Biogen stock on May 15th. The trade occurred in the Representative's "JP MORGAN BROKERAGE ACCOUNT" account.

Representative Robert Bresnahan, Jr. also recently made the following trade(s):

• Sold $1,001 - $15,000 in shares of Zoom Communications NASDAQ: ZM on 6/25/2025.
• Purchased $1,001 - $15,000 in shares of Coinbase Global NASDAQ: COIN on 6/24/2025.
• Purchased $1,001 - $15,000 in shares of Circle Internet Group NYSE: CRCL on 6/24/2025.
• Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 6/23/2025.
• Sold $1,001 - $15,000 in shares of Chubb NYSE: CB on 6/13/2025.
• Sold $1,001 - $15,000 in shares of Atlassian NASDAQ: TEAM on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of ServiceTitan NASDAQ: TTAN on 6/11/2025.
• Sold $1,001 - $15,000 in shares of Datadog NASDAQ: DDOG on 6/11/2025.
• Sold $1,001 - $15,000 in shares of GitLab NASDAQ: GTLB on 6/11/2025.
• Purchased $1,001 - $15,000 in shares of Broadcom NASDAQ: AVGO on 6/11/2025.

Biogen Trading Down 0.8%

BIIB traded down $1.07 on Friday, reaching $131.52. 976,978 shares of the company traded hands, compared to its average volume of 1,173,055. Biogen Inc. has a one year low of $110.04 and a one year high of $219.44. The company has a quick ratio of 1.01, a current ratio of 1.44 and a debt-to-equity ratio of 0.27. The company has a market cap of $19.27 billion, a P/E ratio of 12.98, a price-to-earnings-growth ratio of 1.91 and a beta of 0.14. The firm has a fifty day simple moving average of $129.74 and a two-hundred day simple moving average of $132.51.

Biogen (NASDAQ:BIIB - Get Free Report) last posted its quarterly earnings results on Thursday, May 1st. The biotechnology company reported $3.02 EPS for the quarter, missing the consensus estimate of $3.26 by ($0.24). Biogen had a net margin of 15.07% and a return on equity of 14.03%. The business had revenue of $2.43 billion during the quarter, compared to the consensus estimate of $2.25 billion. During the same quarter in the prior year, the firm posted $3.67 EPS. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. As a group, equities research analysts expect that Biogen Inc. will post 15.83 earnings per share for the current year.

Hedge Funds Weigh In On Biogen

A number of institutional investors have recently modified their holdings of the business. Lee Danner & Bass Inc. purchased a new stake in shares of Biogen during the 4th quarter worth $25,000. Larson Financial Group LLC boosted its position in shares of Biogen by 640.9% in the 4th quarter. Larson Financial Group LLC now owns 163 shares of the biotechnology company's stock worth $25,000 after buying an additional 141 shares in the last quarter. Colonial Trust Co SC boosted its position in shares of Biogen by 9,300.0% in the 4th quarter. Colonial Trust Co SC now owns 188 shares of the biotechnology company's stock worth $29,000 after buying an additional 186 shares in the last quarter. Opal Wealth Advisors LLC purchased a new stake in shares of Biogen in the 1st quarter worth about $26,000. Finally, Greykasell Wealth Strategies Inc. purchased a new stake in shares of Biogen in the 1st quarter worth about $27,000. 87.93% of the stock is owned by institutional investors and hedge funds.

Insider Activity at Biogen

In related news, insider Rachid Izzar sold 2,223 shares of the business's stock in a transaction dated Tuesday, July 8th. The shares were sold at an average price of $135.00, for a total value of $300,105.00. Following the completion of the transaction, the insider owned 6,330 shares of the company's stock, valued at approximately $854,550. The trade was a 25.99% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 0.18% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of research analysts have recently issued reports on the stock. Wedbush reaffirmed a "neutral" rating and issued a $121.00 price objective on shares of Biogen in a research report on Thursday, June 12th. JPMorgan Chase & Co. cut their price objective on shares of Biogen from $185.00 to $175.00 and set a "neutral" rating on the stock in a research report on Monday, May 5th. Morgan Stanley cut their price objective on shares of Biogen from $157.00 to $152.00 and set an "equal weight" rating on the stock in a research report on Wednesday, April 9th. Needham & Company LLC reissued a "hold" rating on shares of Biogen in a research report on Thursday, June 12th. Finally, HSBC downgraded shares of Biogen from a "buy" rating to a "hold" rating and set a $118.00 target price on the stock. in a research report on Monday, April 28th. Twenty-one analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat.com, Biogen presently has a consensus rating of "Hold" and an average price target of $186.37.

About Representative Bresnahan

Rob Bresnahan Jr. (Republican Party) is a member of the U.S. House, representing Pennsylvania's 8th Congressional District. He assumed office on January 3, 2025. His current term ends on January 3, 2027. Bresnahan (Republican Party) is running for re-election to the U.S. House to represent Pennsylvania's 8th Congressional District. He declared candidacy for the 2026 election. Rob Bresnahan Jr. was born in Kingston, Pennsylvania. He earned a B.S. in business administration, management and operations from the University of Scranton in 2012. His career experience includes working as the chief financial officer and CEO of a family business, an electrical contracting company.

About Biogen

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.